Efficacy end points
Depression, ill
SECONDARY, REMISSION
The primary efficacy end point was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from Baseline (Day -1) to three weeks post-psilocybin administration (Week 3) [Key secondary end points included the proportion of participants with a response (defined as a ≥50% improvement in MADRS total score from Baseline) and remission (defined as a MADRS total score ≤10) at Week 3, change from Baseline in Clinical Global Impression–Severity (CGI-S) score at Week 3 and proportion of participants with a response (defined as a score on the CGI-S of 1 (“normal, not ill at all”) or 2 (“borderline mentally ill”)) [